Search clinical trials for: Umeclidinium/vilanterol

Total 88 results

GlaxoSmithKline

Completed

Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children

Asthma

United States, Argentina, Germany, Japan, Chile, Peru, Philippines, Poland, Mexico, Slovakia, Ukraine, South Africa, Puerto Rico, Georgia
GlaxoSmithKline

Completed

A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD

Pulmonary Disease, Chronic Obstructive

Taiwan, China, Philippines, Korea, Republic of
GlaxoSmithKline

Completed

Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry.

Asthma

Korea, Republic of, China, Philippines
Royal College of Surgeons in Ireland - Medical...

Completed

Fluticasone-Vilanterol Once Daily Dose for the Treatment of Mild Asthma in Adults

Asthma

Bahrain
GlaxoSmithKline

Completed

RELOVAIR® Lung Deflation Study

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study

Asthma

United States
GlaxoSmithKline

Withdrawn

A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exercise

Asthma
Bispebjerg Hospital
Rigshospitalet, Denmark

Completed

Urine Concentrations of Vilanterol After Inhaled Administration of Vilanterol/Fluticasone Furoate

Pharmacokinetics

Denmark
Chinese SLE Treatment And Research Group
Beijing Life oasis public service center

Not yet recruiting

A Study on the Prevention and Treatment of GIOP With Eldecalcitol (ELEGANT)

Rheumatoid Arthritis | Osteoporosis | Osteopenia

China
GlaxoSmithKline

Completed

Relovair PD PK in Chinese Healthy Subjects

Asthma

China
GlaxoSmithKline

Completed

Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response

Asthma

United Kingdom, Germany, New Zealand
University of Saskatchewan

Completed

Effect of Vilanterol on Methacholine Challenge Results

Asthma

Canada
Morten Hostrup, PhD

Recruiting

Role of Lung Function for Exercise Capacity in Well-trained Individuals

Exercise Performance

Denmark
GlaxoSmithKline

Completed

Bioequivalence Study to Compare Fluticasone Furoate (FF) 1-strip Inhaler With FF 2-strip Inhaler and With FF/Vilanterol Combination

Asthma

Germany
GlaxoSmithKline

Completed

A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients.

Asthma

New Zealand
GlaxoSmithKline

Completed

Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

Asthma

United States, Germany, Japan, Romania, Ukraine, Poland
GlaxoSmithKline

Completed

An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma

Asthma

United Kingdom
GlaxoSmithKline

Completed

Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)

Asthma

United States, Canada
GlaxoSmithKline

Completed

A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects

Asthma

Japan
GlaxoSmithKline

Completed

24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Argentina, Australia, United States, Germany, Chile, Korea, Republic of, Mexico, Canada, South Africa, Romania
GlaxoSmithKline

Completed

Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

Asthma

United States, Germany, Japan, Romania, Russian Federation, Poland
GlaxoSmithKline

Completed

Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an Inhaler

Asthma

United Kingdom
GlaxoSmithKline

Completed

Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma

Asthma

Germany, Ukraine, United States, Peru, Poland
GlaxoSmithKline

Completed

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease

Pulmonary Disease, Chronic Obstructive

United States, Canada, Germany, Romania, Poland, Czechia
Abbott

Completed

A Study of Pain Relief in Osteoarthritis

Osteoarthritis

United States
University of Dundee
Boehringer Ingelheim; NHS Tayside

Completed

INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and Olodaterol (INCOGNITO)

Chronic Obstructive Pulmonary Disease

United Kingdom
Mundipharma Research Limited

Completed

A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar® Ellipta® DPI on Ventilation Heterogeneity in Asthma

Asthma

United Kingdom, Sweden, Australia, New Zealand, Slovakia
GlaxoSmithKline

Completed

A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD

Pulmonary Disease, Chronic Obstructive

Argentina, France, Germany, Russian Federation, Ukraine, Italy, Norway
GlaxoSmithKline
Parexel

Withdrawn

The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on Asthma

Asthma
GlaxoSmithKline

Completed

A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))

Pulmonary Disease, Chronic Obstructive

France, Germany, Spain, Russian Federation, Belgium, Ukraine, Philippines, Italy, Poland
Rambam Health Care Campus

Completed

Effect of Fluticasone Furoate/Vilanterol on EIA in Adolescents (EIA)

Asthma in Children

Israel
GlaxoSmithKline

Completed

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Germany, Poland, Romania, United States, Czechia, Russian Federation
GlaxoSmithKline

Completed

HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents

Asthma

United States, Argentina, Korea, Republic of, Netherlands, Philippines, Chile
GlaxoSmithKline

Completed

A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma

Asthma

Germany, France
GlaxoSmithKline

Completed

Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Ukraine, Spain, South Africa, Italy
GlaxoSmithKline

Completed

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma

Asthma

United States, Argentina, Germany, Korea, Republic of, Romania, Russian Federation, Spain, Netherlands, Mexico, Brazil, Chile, Czechia
Chiesi Farmaceutici S.p.A.

Withdrawn

TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD

COPD
University of Oxford
Bill and Melinda Gates Foundation; Department for International Development... and other collaborators

Recruiting

Randomised Evaluation of COVID-19 Therapy (RECOVERY)

Severe Acute Respiratory Syndrome

Ghana, Indonesia, Nepal, South Africa, United Kingdom, Vietnam, India

3

Subscribe